OKYO Pharma: Chairman's associate buys 80,000 shares
Ticker: OKYO · Form: 6-K · Filed: Sep 5, 2024 · CIK: 1849296
Sentiment: neutral
Topics: insider-transaction, share-purchase
TL;DR
OKYO Pharma exec chairman's associate bought 80k shares, signaling potential confidence.
AI Summary
On September 5, 2024, OKYO Pharma Ltd announced that Panetta Partners Limited, an entity associated with Executive Chairman Gabriele Cerrone, acquired 80,000 ordinary shares of the company. The filing does not specify the price or total value of this transaction.
Why It Matters
This purchase by an entity with a beneficial interest from the Executive Chairman could signal confidence in the company's future prospects.
Risk Assessment
Risk Level: low — The filing reports a share purchase by an entity associated with the Executive Chairman, which is a common disclosure and does not inherently indicate significant new risks.
Key Numbers
- 80,000 — Shares Purchased (Number of ordinary shares acquired by Panetta Partners Limited)
Key Players & Entities
- OKYO Pharma LTD (company) — Company filing the report
- Panetta Partners Limited (company) — Entity that purchased shares
- Gabriele Cerrone (person) — Executive Chairman with beneficial interest in Panetta Partners Limited
- 80,000 (dollar_amount) — Number of ordinary shares purchased
FAQ
What was the date of the notification regarding the share purchase?
The notification was made on September 5, 2024.
Who is Gabriele Cerrone in relation to OKYO Pharma?
Gabriele Cerrone is the Executive Chairman of OKYO Pharma LTD.
Which entity purchased the ordinary shares?
Panetta Partners Limited purchased the ordinary shares.
How many ordinary shares were purchased?
80,000 ordinary shares were purchased.
Does the filing specify the price or total value of the share purchase?
No, the filing does not specify the price or total value of the share purchase.
Filing Stats: 373 words · 1 min read · ~1 pages · Grade level 13.4 · Accepted 2024-09-05 07:00:24
Key Financial Figures
- $1.15 — dinary shares on NASDAQ at a price of US$1.15 per share. This brings the total shareh
Filing Documents
- form6-k.htm (6-K) — 25KB
- ex99-1.htm (EX-99.1) — 9KB
- ex99-1_001.jpg (GRAPHIC) — 26KB
- 0001493152-24-035081.txt ( ) — 71KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. OKYO Pharma LTD Date: September 5, 2024 By: /s/ Keeren Shah Name: Keeren Shah Title: Chief Financial Officer 3 EXHIBIT INDEX Exhibit No. Description 99.1 News Announcement, dated September 5, 2024 4